PCSK9 Forum
July 2014
Facebook Twitter RSS
For latest updates
Register today
Home About PCSK9 Forum News Expert Opinion Education & Resources Register
Newsletter - July 2014

Focus on Unmet Clinical Needs:
Familial Hypercholesterolaemia (FH)

From the Editors: Missing FH - How can we improve FH referral and diagnosis?
According to Prof. Raul Santos, Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil, light is starting to appear at the end of the FH tunnel...

Improving FH detection in primary care: UK Medway CCG FH Audit Programme warrants wider rollout

PCSK9: Opportunities for personalised medicine in FH?
Dr. Marina Cuchel, University of Pennsylvania, Philadelphia, USA comments on new data showing that PCSK9 gain of function mutations are relatively common in FH patients in Japan.

State of the Science: The FH enigma - Does whole exome sequencing provide insights?

Exclusive interviews

FH management in low- to middle-income countries
Dr. Dirk Blom, University of Cape Town, South Africa, provides a perspective

Hot Topics

How low should LDL-C be lowered: Thoughts of IMPROVE-IT put this back on the agenda

Video: Dr. Evan Stein: Lowering LDL-C: How low and for how long?
Video: Prof. Henry Ginsberg: LDL-C: How low should clinicians aim for?

Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite link

Our mission

Our goal

In the next 3 years the PCSK9 Education and Research Forum will become a major, globally-recognised source of independent, scientific knowledge of the critical importance of PCSK9 inhibition in the search for treatments which promise to transform the prognosis of millions of people with atherosclerotic dyslipidaemia.

Our response to this challenge

Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Our partnership and outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes.
About PCSK9 Education and Research Forum

Watch the Aims & Objectives video
Read our Mission Statement
Partnership and outreach
Meet our Editorial Board
View Forthcoming Meetings

Video: Prof Kosh Ray, UK: Residual cardiovascular risk – a role for PCSK9 inhibition
Video: Dr Dirk Blom, South Africa: FH issues in low to middle income regions
Video: Dr Dirk Blom, South Africa: The role of PCSK9 inhibitors in FH

Read more news »
Hot topics

Video: Lowering LDL-C: How low and for how long?
Dr Evan Stein
Video: LDL-C: how low should clinicians aim for?
Prof Henry Ginsberg

FH Challenges: Improving FH detection in primary care: a UK audit tool

Opportunities for personalised medicine in FH? Marina Cuchel

The FH enigma: are there other FH-causing genes? A genetic diagnosis is established in about 80% of patients with FH.

  Supported by educational grants from: Amgen Lilly pFizer Sanofi  
Copyright PCSK9 Forum 2014. Please click here to unsubscribe from future mailings.